Clinical Development Times for Biosimilars in the United States
- 1 October 2020
- journal article
- research article
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 95 (10) , 2152-2154
Abstract
No abstract availableKeywords
Funding Information
- Arnold Ventures
This publication has 7 references indexed in Scilit:
- Why Are Biosimilars Not Living up to Their Promise in the US?AMA Journal of Ethics, 2019
- The US Biosimilar Market: Stunted Growth and Possible ReformsClinical Pharmacology & Therapeutics, 2018
- Obstacles to the Adoption of Biosimilars for Chronic DiseasesJAMA, 2017
- Clinical trial cycle times continue to increase despite industry effortsNature Reviews Drug Discovery, 2017
- Progress and Hurdles for Follow-on BiologicsNew England Journal of Medicine, 2015
- Are trade secrets delaying biosimilars?Science, 2015
- Economics of New Oncology Drug DevelopmentJournal of Clinical Oncology, 2007